Severe chronic rhinosinusitis is a debilitating disease with a significant impact on quality of life. Treatment options are limited, and until recently, little progress had been made in developing new treatments. As of 18th March 2021, Xolair (omalizumab) is TGA-approved for the treatment of severe chronic rhinosinusitis with nasal polyps. We review data from the ...
Xolair approved for treatment of severe CRSwNP
3 Jun 2021
Sponsored by Novartis